Fake pharmaceuticals worth CHF 210bn are entering our ecosystem every year > worldwide, about 10% of all drugs in circulation are fake & 50% of drugs sold on the internet are fake, illegal pharma market grows at 13% CAGR – twice the rate of the legal pharma market
Complex, intransparent and long pharma supply chain is vulnerable and leaves room for entry of poor quality and illicit drugs, 30 handovers until the medicine reaches the patient are not uncommon
Today’s control focus is on packaging – defensive measures (eg. Serialization EN2016/161) are not good enough, as they do not provide any information on the drug inside
1 million patients die annually from toxic counterfeit pharmaceuticals
Improves product- and patient-safety
Enables finished product authentication through packaging
Reduces the incoming goods burden
Replaces time consuming and costly traditional bio lab testing methods
Defends the legal pharmaceutical distribution chain – acts as «firewall»
Renders end-to-end data along the distribution chain possible (data transparency, intelligence, big data)
Adds early detection capabilities
Distribution Partners (e.g. Pre-Wholesaler, Wholesaler, Distributor, Retailer, Online-Retailer) of the Marketing Authorization Holders (PharmaCo).
Leading University and large Hospitals Worldwide.
Government Authorities, Regulatory Bodies, Customs and Border Protection